Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Friborg, Jacques ^a   Ross Macdonald, Petra ^b   Cao, Jian ^b   Willard, Ryan ^a   Lin, Baiqing ^a   Eggers, Betsy ^a   McPhee, Fiona ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ALPHA INTERFERON RECEPTOR; ANTIVIRUS AGENT; I KAPPA B KINASE EPSILON; INTERFERON LAMBDA RECEPTOR SUBUNIT IL28RA; INTERFERON RECEPTOR; JANUS KINASE; PEGINTERFERON ALPHA; PEGINTERFERON LAMBDA; PROTEIN CARDIF; PROTEIN USP18; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TYPE 1 INTERFERON ALPHA RECEPTOR SUBUNIT 1; UBIQUITIN; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; IFNAR1 PROTEIN, HUMAN; INTERFERON; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTERFERON INDUCTION; INTRACELLULAR SIGNALING; LIVER CELL; NONHUMAN; TRANSCRIPTION REGULATION; UPREGULATION; VIRAL CLEARANCE; VIRION; VIRUS IMMUNITY; VIRUS REPLICATION; CELL CULTURE; GENETICS; HEPACIVIRUS; METABOLISM; PATHOGENICITY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

HEPATITIS C VIRUS;

CELLS, CULTURED; DOWN-REGULATION; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON TYPE I; RECEPTOR, INTERFERON ALPHA-BETA; RNA, VIRAL; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 84926364225     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121734     Document Type: Article

References (62)

1. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. The New England journal of medicine. 2006; 355(23):2444-51. PMID: 17151366
2. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. The New England journal of medicine. 2011; 364(13):1195-206. doi: 10.1056/NEJMoa1010494 PMID: 21449783
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England journal of medicine. 2011; 364(25):2405-16. doi: 10.1056/NEJMoa1012912 PMID: 21696307
4. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20):1878-87. doi: 10.1056/NEJMoa1214853 PMID: 23607594
5. Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Simeprevir with pegin-terferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. Journal of hepatology. 2014; 61(2):219-27. doi: 10.1016/j.jhep.2014.04.004 PMID: 24727123
6. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. The New England journal of medicine. 2011; 364(13):1207-17. doi: 10.1056/NEJMoa1009482 PMID: 21449784
7. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. The New England journal of medicine. 2010; 362(14):1292-303. doi: 10.1056/NEJMoa0908014 PMID: 20375406
8. Chevaliez S, Asselah T. Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clinics and research in hepatology and gastroenterology. 2011; 35 Suppl 1:S31-41. doi: 10.1016/S2210-7401(11)70005-5 PMID: 21742299
9. Li K, Lemon SM. Innate immune responses in hepatitis C virus infection. Seminars in immunopathology. 2013; 35(1):53-72. doi: 10.1007/s00281-012-0332-x PMID: 22868377
10. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. doi: 10.1038/nature09907 PMID: 21478870
11. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005; 436(7053):946-52. PMID: 16107834
12. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nature medicine. 2013; 19(7):879-88. doi: 10.1038/nm.3253 PMID: 23836238
13. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008; 105(19):7034-9. doi: 10.1073/pnas.0707882105 PMID: 18467494
14. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut. 2008; 57(4):516-24. PMID: 17895355
15. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2011; 140(3):1021-31. doi: 10.1053/j.gastro.2010.11.039 PMID: 21111740
16. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem cells. 2001; 19 (5):378-87. PMID: 11553846
17. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/ UBP43. Mol Cell Biol. 2009; 29(17):4841-51. doi: 10.1128/MCB.00224-09 PMID: 19564419
18. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One. 2011; 6(7):e22200. doi: 10.1371/journal.pone.0022200 PMID: 21779393
19. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, et al. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology. 2011; 54 (6):1913-23. doi: 10.1002/hep.24580 PMID: 21800339
20. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012; 142(4):978-88. doi: 10.1053/j.gastro.2011.12.055 PMID: 22248663
21. Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012; 9(7):406-17. doi: 10.1038/nrgastro.2012.101 PMID: 22641049
22. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, et al. Pegylated Interferon-Lambda (PegIFN-ë) Shows Superior Viral Response With Improved Safety and Tolerability Versus PegIFN-α-2a in HCV Patients (G1/2/3/4): EMERGE Phase IIb Through Week 12. Journal of Hepatology. 2011; 54 (supplement 1):S538-S9.
23. Zeuzem SA, Bacon B, Box T, Charlton M, Diago M, Dieterich D, et al. Peginterferon Lambda-1A (Lambda) Compared With Peginterferon Alfa-2A (Alfa) in Treatment- Naive Patients With HCV Genotypes 2 or 3: First SVR24 Results From EMERGE Phase IIb. Journal of Hepatology. 2012; 56(supplement 2): S5-S6.
24. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014; 61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022 PMID: 25064437
25. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43(5):954-60. PMID: 16628671
26. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129(2):522-7. PMID: 16083709
27. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. The Journal of infectious diseases. 2000; 182(1):28-35. PMID: 10882578
28. Gupta S, Singh R. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response. PLoS One. 2012; 7(7):e41209. doi: 10.1371/journal.pone.0041209 PMID: 22911761
29. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998; 282(5386):103-7. PMID: 9756471
30. Freeman JA, Gray TE, Fontana D, Lopez-Talavera JC, Wind-Rotolo M, Emison E, et al. Effect of Treatment Group, HCV Genotype, and IL28B Genotype on Early HCV Viral Kinetics in a Phase 2a Study of PEG-Interferon Lambda (pegIFNë) in Hepatitis C Patients. Hepatology. 2010; 52(S1):721A.
31. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrobial agents and chemotherapy. 2012; 56(10):5387-96. doi: 10.1128/AAC.01186-12 PMID: 22869577
32. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science. 2005; 309(5734):623-6. PMID: 15947137
33. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(26):9294-9. PMID: 15939869
34. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, et al. Multiple-laboratory comparison of microarray platforms. Nature methods. 2005; 2(5):345-50. PMID: 15846361
35. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 2007; 35(Database issue): D61-5. PMID: 17130148
36. Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, et al. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrobial agents and chemotherapy. 2013; 57(3):1312-22. doi: 10.1128/AAC.02239-12 PMID: 23274666
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8. PMID: 11846609
38. Wu X, Robotham JM, Lee E, Dalton S, Kneteman NM, Gilbert DM, et al. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog. 2012; 8(4):e1002617. doi: 10.1371/journal.ppat.1002617 PMID: 22496645
39. Schwartz RE, Trehan K, Andrus L, Sheahan TP, Ploss A, Duncan SA, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012; 109(7):2544-8. doi: 10.1073/pnas.1121400109 PMID: 22308485
40. Wolk B, Sansonno D, Krausslich HG, Dammacco F, Rice CM, Blum HE, et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tet-racycline-regulated cell lines. Journal of virology. 2000; 74(5):2293-304. PMID: 10666260
41. Lamken P, Lata S, Gavutis M, Piehler J. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J Mol Biol. 2004; 341(1):303-18. PMID: 15312780
42. Roisman LC, Jaitin DA, Baker DP, Schreiber G. Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. J Mol Biol. 2005; 353 (2):271-81. PMID: 16171819
43. Wieland S, Makowska Z, Campana B, Calabrese D, Dill MT, Chung J, et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology. 2014; 59(6):2121-30. doi: 10.1002/hep.26770 PMID: 24122862
44. Garaigorta U, Heim MH, Boyd B, Wieland S, Chisari FV. Hepatitis C virus (HCV) induces formation of stress granules whose proteins regulate HCV RNA replication and virus assembly and egress. Journal of virology. 2012; 86(20):11043-56. PMID: 22855484
45. Ank N, Paludan SR. Type III IFNs: new layers of complexity in innate antiviral immunity. BioFactors. 2009; 35(1):82-7. doi: 10.1002/biof.19 PMID: 19319850
46. Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 2003; 22(3):537-47. PMID: 12554654
47. Marijanovic Z, Ragimbeau J, Kumar KG, Fuchs SY, Pellegrini S. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem J. 2006; 397(1):31-8. PMID: 16551269
48. Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, et al. HCV infection selectively impairs type I but not type III IFN signaling. The American journal of pathology. 2014; 184(1):214-29. doi: 10.1016/j.ajpath.2013.10.005 PMID: 24215913
49. Morita K, Tanaka K, Saito S, Kitamura T, Kondo M, Sakaguchi T, et al. Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J Clin Gastroenterol. 1998; 26(2):135-40. PMID: 9563926
50. Meng XW, Chi BR, Chen LG, Zhang LL, Zhuang Y, Huang HY, et al. Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol. 2005; 11(25):3962-5. PMID: 15991303
51. Larrea E, Aldabe R, Molano E, Fernandez-Rodriguez CM, Ametzazurra A, Civeira MP, et al. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut. 2006; 55(8):1188-96. PMID: 16120756
52. Lalle E, Bordi L, Caglioti C, Garbuglia AR, Castilletti C, Taibi C, et al. IFN-Alpha receptor-1 upregulation in PBMC from HCV naive patients carrying cc genotype. possible role of IFN-lambda. PloS one. 2014; 9(4):e93434. doi: 10.1371/journal.pone.0093434 PMID: 24691098
53. Goossens N, Negro F. Is the genotype 3 of the hepatitis C virus the new villain? Hepatology. 2013.
54. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368 (20):1867-77. doi: 10.1056/NEJMoa1214854 PMID: 23607593
55. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 2006; 44(4):896-906. PMID: 17006906
56. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006; 131(6):1887-98. PMID: 17087946
57. Freeman J, Baglino S, Friborg J, Kraft Z, Gray T, Hill M, et al. Pegylated interferons Lambda-1a and alfa-2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells. J Viral Hepat. 2014; 21(6):e1-9. doi: 10.1111/jvh.12243 PMID: 24827902
58. Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, Golden-Mason L, et al. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 2013; 9(4):e1003316. doi: 10.1371/journal.ppat.1003316 PMID: 23637605
59. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology. 2013; 144(2):414-25 e7. doi: 10.1053/j.gastro.2012.10.034 PMID: 23089201
60. Heim MH. Innate immunity and HCV. J Hepatol. 2013; 58(3):564-74. doi: 10.1016/j.jhep.2012.10.005 PMID: 23063572
61. Ding Q, Huang B, Lu J, Liu YJ, Zhong J. Hepatitis C virus NS3/4A protease blocks IL-28 production. European journal of immunology. 2012; 42(9):2374-82. doi: 10.1002/eji.201242388 PMID: 22685015
62. Lee HC, Narayanan S, Park SJ, Seong SY, Hahn YS. Transcriptional regulation of IFN-lambda genes in hepatitis C virus-infected hepatocytes via IRF-3.IRF-7.NF-kappaB complex. J Biol Chem. 2014; 289 (17):11861.